Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T. Nakao A, et al. Among authors: teshigahara o. Curr Cancer Drug Targets. 2007 Mar;7(2):169-74. doi: 10.2174/156800907780058808. Curr Cancer Drug Targets. 2007. PMID: 17346108 Clinical Trial.
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, Kimura Y, Komino M, Arai H, Morikawa T, Motohashi I, Miyazawa R, Moriyama T, Kamura H, Terada M, Kuwamitsu O, Hayakawa T, Sando E, Ohara Y, Teshigahara O, Suzuki M, Morimoto K. Maeda H, et al. Among authors: teshigahara o. Clin Infect Dis. 2022 Nov 30;75(11):1971-1979. doi: 10.1093/cid/ciac292. Clin Infect Dis. 2022. PMID: 35438137 Free PMC article.
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Masuda S, Osawa R, Hosokawa N, Nakashima K, Kamura H, Imura H, Inoue H, Matsuzaka S, Sugimoto Y, Kuwamitsu O, Motohashi I, Morikawa T, Oda R, Hoshina Y, Matono T, Teshigahara O, Sando E, Asami S, Kudo S, Akizuki N, Muto Y, Hayakawa T, Kishaba T, Ohara Y, Kubo Y, Suzuki M, Morimoto K. Maeda H, et al. Among authors: teshigahara o. Expert Rev Vaccines. 2024 Jan-Dec;23(1):213-225. doi: 10.1080/14760584.2024.2310807. Epub 2024 Feb 8. Expert Rev Vaccines. 2024. PMID: 38288980 Free article.
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y, Komino M, Arai H, Kuwamitsu O, Akuzawa N, Sando E, Morikawa T, Imura H, Inoue H, Hayakawa T, Teshigahara O, Ohara Y, Suzuki M, Morimoto K. Maeda H, et al. Among authors: teshigahara o. Expert Rev Vaccines. 2023 Jan-Dec;22(1):288-298. doi: 10.1080/14760584.2023.2188950. Expert Rev Vaccines. 2023. PMID: 36883371 Free article.